as 10-17-2025 3:59pm EST
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
Founded: | 2003 | Country: | Switzerland |
Employees: | N/A | City: | N/A |
Market Cap: | 869.8M | IPO Year: | N/A |
Target Price: | $41.00 | AVG Volume (30 days): | 77.9K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -2.92 | EPS Growth: | N/A |
52 Week Low/High: | $14.00 - $23.08 | Next Earning Date: | 11-06-2025 |
Revenue: | $960,668 | Revenue Growth: | -12.29% |
Revenue Growth (this year): | 36.75% | Revenue Growth (next year): | 1261.53% |
OCS Breaking Stock News: Dive into OCS Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
GlobeNewswire
5 days ago
Zacks
9 days ago
Simply Wall St.
10 days ago
GlobeNewswire
10 days ago
MT Newswires
13 days ago
GlobeNewswire
13 days ago
Zacks
a month ago
The information presented on this page, "OCS Oculis Holding AG Ordinary shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.